

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1532750> since 2016-10-10T17:28:30Z

Published version:

DOI:10.1053/j.semdp.2015.10.009

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?

Giuseppe Pelosi, MD, MIAC,*^{1,2} Alessandra Fabbri, MD,¹ Mara Cossa, MD,¹ Angelica Sonzogni, MD,¹ Barbara Valeri, MD,¹ Luisella Righi, MD,³ Mauro Papotti, MD³

¹ Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

² Department of Biomedical and Clinical Sciences “Luigi Sacco”, Università degli Studi, Milan, Italy

³ Department of Pathology, University of Torino, Torino, Italy

Short title: Neuroendocrine tumors of the lung

Conflict of interest statement: The Authors declare that they have no conflicts of interest.

This work was supported by LILT (Lega Italiana per la Lotta contro i Tumori, Sezione di Milano, Milan, Italy). The Funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, which are responsibilities of the Authors only. This work is dedicated to the memory of Carlotta, an extraordinarily lively girl who untimely died of cancer in the prime of life.

Mailing address for correspondence:

Giuseppe Pelosi, MD, MIAC
Dipartimento di Patologia Diagnostica e Laboratorio
Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
I-20133 Milano
ITALY
phone: + 39 02 23902260/2876/3017
fax: + 39 02 23902877
E-mail: giuseppe.pelosi@unimi.it

Abstract

Lung neuroendocrine tumors (NET) are currently classified in resection specimens according to four histological categories, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC). Diagnostic criteria have remained unchanged in the 2015 WHO classification, which has ratified the wide acceptance and popularity of such terminology in the pathologists' and clinicians' community. A unifying umbrella of NE morphology and differentiation has been recognized in lung NET, which has pushed to enter an unique box of invasive tumors along with diffuse idiopathic pulmonary NE cell hyperplasia (DIPNECH) as a pre-invasive lesion with a potential towards the development of carcinoids. However, uncertainties remain in the terminology of lung NET upon small samples, where Ki-67 antigen could play some role to avoid misdiagnosing carcinoids as high-grade NE tumors. Epidemiologic, clinical and genetic traits support a biological three-tier over a pathology four-tier model, according to which TC are low malignancy tumors, AC intermediate malignancy tumors and LCNEC/SCC high malignancy tumors with no significant differences in survival among them. Inconsistencies in diagnostic reproducibility, troubles in the therapy of AC and LCNEC, and limitations to histology within the same tumor category argue in favor of a global re-thinking of lung NET where a grading system could play a role. This review outlines three main key-questions in the field of lung NET: a) unbiased diagnoses, b) the role of Ki-67 and tumor grading, and c) management of predictive markers. Answers are still inconclusive, thus additional research is required to improve our understanding on lung NET.

Key words: neuroendocrine, tumor, carcinoid, large cell, small cell, diagnosis, immunohistochemistry, grading, Ki-67, prognosis, survival, predictive, molecular pathology

Approaching lung NET

The new 2015 WHO classification on lung neuroendocrine tumors (NET) ¹ has substantially confirmed the four widely-agreed upon histological variants crystallized in the two previous editions of 1999 ² and 2004 ³, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC). Remarkably, in this 2015 edition, these tumors have been pushed to enter a unique box of NE proliferations by moving LCNEC from the all-inclusive chapter of large cell carcinoma, and adding diffuse idiopathic pulmonary NE cell hyperplasia (DIPNECH) as a pre-invasive lesion with a potential towards the development of carcinoids ¹. There are several practical reasons why this traditional terminology of lung NET has been retained in the new 2015 WHO classification, which is the result of widely shared expert opinions according to the current state of the art ^{1,4}. The term carcinoid, either typical or atypical, has been gaining wide popularity and diagnostic awareness among pathologists and clinicians while valuable alternatives are still lacking ^{1,4}. Likewise, the other two histological variants, either LCNEC or SCC, are deemed to be full-blown high-grade carcinomas occurring in either pure or combined forms, which are almost relentlessly characterized by aggressive clinical behavior and dismal prognosis ^{1,4-8}.

There is general agreement that this four-tiered histological classification is consistent with an operational three-tier prognostic scheme on the basis of epidemiological (age, sex, smoking habit), genetic (association with MEN1 syndrome and several other gene pathways), clinical (lymph node and distant metastases, association with paraneoplastic syndromes, type and response to therapy) and behavioral traits, which results in progressive grades of biological aggressiveness ^{1,9-14}. Accordingly, TC is deemed to be a low-grade malignant tumor with longer life expectation and time to recurrence, AC an intermediate-grade malignant tumor with more aggressive clinical course, somewhat unpredictable clinical behavior and shorter time to recurrence, and LCNEC and SCC high-grade malignant tumors with dismal prognosis, challenging therapy options and, often, difficulties in reliably distinguishing from each others, either pathologically, genetically or clinically ^{1,4,8,14-19}.

As a function of cell differentiation and in keeping with the recent European Neuroendocrine Tumor Society (ENETS) guidelines ⁴ and the current WHO classification ¹,

TC and AC as a whole are considered well-differentiated NE tumors because of their resemblance to the normal cell counterpart of the NE diffuse system or pre-invasive lesions, such as DIPNECH, as opposed to LCNEC and SCC, which are thought to make up a poorly differentiated tumor group^{1, 20, 21}. As a matter of fact, TC and AC feature organoid growth patterns, typical to slight atypical cytology (even though they may uncommonly exhibit prominent nuclear pleomorphism) (**Figure 1**), absent to focal punctate necrosis, up to 10 mitoses per 2 mm² and consistent labeling for pan-NE markers, such as chromogranin A and synaptophysin, sometimes less intense and uneven in the setting of AC^{1, 4, 12, 14}. On the contrary, SCC and LCNEC show solid growth patterns, extensive/geographic necrosis, mitotic count higher than 10 mitoses per 2 mm², and uneven labeling for pan-NE markers^{1, 4, 12, 14}. Cytological criteria are then used to split SCC from LCNEC, although there is a considerable morphologic overlap between them making this separation quite subjective and difficult to carry out, with disappointingly low inter-observer diagnostic reproducibility^{12, 15, 16, 22-25}.

The molecular scenario of lung NET has been pushed to emerge by several studies confirming the assumption that there are two distinct groups in lung NET. As a matter of fact a dichotomous separation between low to intermediate malignancy tumors on the one hand (i.e., TC and AC) and high malignancy tumors on the other hand (i.e., SCC and LCNEC) is solidified by substantial differences in gene pathway alterations, levels of differentiation and cell derivation^{8, 12, 26-32}. Accordingly, it is not surprising that common genetic traits may be shared by each of these two broad tumor categories, with TC/AC on the one hand and LCNEC/SCLC on the other hand exhibiting major differences in the somatic mutation rates and engagement of diverse gene pathways^{8, 12, 26-33}. A further inherent molecular heterogeneity, however, is found within each histological variant on the basis of several functional and genetic biomarkers, which may identify different patient subsets with different prognosis^{31, 34-37}.

All these assumptions suggest the opportunity to reevaluate lung NET keeping in mind that all lung NET are malignant, that the malignancy rate has to be quantified for clinical purposes of personalized therapy, and that malignancy depends on several biological and functional factors, among which a grading system specifically devised for the lung could play a pivotal role¹³. The ultimate and ambitious goal is to improve our understanding in the field

of lung NET tumors, placing them into context for the best management practice of these patients.

Designing the article

A review of papers reported on the issues of lung NET with special reference to diagnosis, Ki-67, grading and predictive markers was performed until July 2015, taking advantage of a list of key questions for either subject. We limited our bibliography research to the English literature, apart from some historical papers published in other languages. Only full papers of peer-reviewed journals were considered. Research terms included carcinoid, typical, atypical, small cell, large cell, LCNEC, SCLC, intermediate, neuroendocrine, Ki-67, proliferation, grading, mitoses, count, necrosis, DNA, square millimeter, next generation, prognosis, survival, predictive factors, aggressiveness, therapy, targeted, sequencing, genome, exome, exon, genomic, landscape, portrait, whole, transcriptome, expression, high-throughput, thymidylate synthase, fluoropyrimidine therapy, excision repair cross-complementation 1 (ERCC 1), somatostatin receptors, mammalian target of rapamycin (mTOR), and prediction. This article was not designed to make up an exhaustive overview on the current knowledge about lung-NET, but rather to critically reappraise and rethink these tumors in light of emerging issues and questions, which often arise among physicians who treat these tumors daily within operating multidisciplinary teams. The ultimate goal was to focus on practical aspects of the fascinating world of lung-NET to answer practical questions. Specifically, we have herein developed three main key-questions, which clinicians could like to ask pathologists whenever facing lung NET. They are relative to the need: a) to have more precise and unbiased diagnoses; b) to unravel the role of prognostic factors with particular emphasis to Ki-67 labeling index and tumor grading; and c) to use predictive markers in the clinical management of these tumor patients. The following exposition will follow these three main key-questions, in light of recently published papers.

Diagnosing lung NET

Diagnosis still remains the first but no longer the only task clinicians are requiring to pathologists whenever facing lung NET. Some entities proposed over time in the field of lung

NET may be considered milestones with direct and continuing integration to the current terminology, while other terms or taxonomy schemes are only a historical inheritance (at least according to recent guidelines ⁴ and WHO classification ¹). Diagnostic criteria for SCC - as we still know and currently rely on - date basically back to Azzopardi's publication of 1959 ³⁸, where the appellation of oat cell carcinoma reappraised the previous concept of small-celled sarcoma by Barnard of 1926 ³⁹. The term AC was introduced in 1972 by Arrigoni ⁴⁰ taking advantage of necrosis, increased mitoses, disorganized architecture and cell atypia to enucleate lung carcinoid patients characterized by more aggressive clinical course from the preexisting category of bronchial carcinoid/adenoma as authored by Hamperl in 1937 ⁴¹, who extended to the lung the entity initially recognized and described in the small intestine by Oberndorfer in 1907 ^{42, 43}. Subsequently, diagnostic criteria for AC were definitely outlined by Travis in 1998 ⁷, which retained both name and defining features with no remarkable changes in the subsequent three WHO classifications of 1999 ², 2004 ³ and 2015 ¹. LCNEC as high-grade tumor intermediate behaviorally between AC and SCLC was authored by Travis in 1991 ⁴⁴, which showed striking similarities to NE carcinoma of intermediate cell type described by Gould of 1983 ⁴⁵. In 1998, this entity was confirmed in its current diagnostic attributes ⁷ and inter-observer reproducibility ⁶, but survival rate was equaled to that of SCC.

Many other classifications and terminologies have been proposed over time on lung NET, whose detailed examination is beyond the scope of the current paper, by either introducing a concept of tumor grading ^{11, 13, 46-49}, applying different thresholds to current defining criteria ^{50, 51} or extending to these tumors the same defining criteria as those used in the gastroenteropancreatic tract ^{21, 52-54}. These different proposals, however, have not gained wide acceptance yet because of the lack of clear clinical advantages over the last three WHO classifications on lung cancer, which represented the gold standard for these tumors. ¹⁻³. Suffice to say that lung NET have maintained the same terminology and defining criteria of the past 16 years, making them popular among pathologists and clinicians and justifying their application to the current clinical management. However, the diagnostic inter-observer reproducibility among the diverse categories of lung NET still remains an unanswered question ^{6, 15, 16, 23, 55-59}, as well as difficulties in identifying different patient subsets with different clinical behavior within the same histological variant or stage of disease, or in

correctly diagnosing non-resection specimens ^{1,4}. While it is reasonable that no classification is able to predict all exceptions, there are some open questions regarding the current taxonomy on lung NET, which we have been summed up in **Table 1**.

It is well established that the diagnosis of lung NET is a stepwise process ²², according to which NE architecture is recognized at first and then tumors are divided into four diagnostic categories on the basis of the number of mitoses per 2 mm² and the presence (and extent) of necrosis ^{1,4}. Additional criteria include the demonstration of pan-NE markers upon immunohistochemistry (IHC) to split LCNEC from large cell carcinoma with NE morphology or more conventional non-small cell carcinomas and a constellation of cyto-morphologic features to separate LCNEC from SCLC ¹. A synopsis of diagnostic criteria in resection specimens as outlined by the recent 2015 WHO classification is reported in **Table 2**, while representative pictures of the four tumor categories according to these criteria are depicted in **Figure 2**.

Despite the presence of a general unanimous separation between the two ends of the lung NET spectrum, i.e. TC and SCLC, at least in surgical specimens, major diagnostic concerns emerge for adjacent categories whenever addressing boundary or gray zone tumors where the subjective application of defining criteria (mainly mitoses and necrosis) may encounter difficulties in their ultimate diagnostic attribution, i.e. TC vs. AC, AC vs. LCNEC, and LCNEC vs. SCLC ^{6, 15, 16, 23, 55-59}. Detailed studies on the clinico-pathologic features of these boundary or gray zone lung NET are still lacking, but it is well known that AC showing a number of mitoses comprised between 6 and 10 per 2 mm² run a worse clinical course ⁶⁰, and that on the contrary about 15-20% of SCC or LCNEC patients experience long survival ^{7, 10, 13, 59, 61, 62}. There are a number of issues accounting for inconsistency between morphology and clinical behavior ^{6, 12, 63}. Difficulties in recognizing mitoses and necrosis in the group of TC and AC ⁵⁵ and variability in assessing cell size and cytological features in the group of LCNEC and SCLC ^{6, 15, 16, 23, 57} may explain inconsistencies in the diagnostic reproducibility of lung NET. Additional criteria, such as the labeling for mitosis-specific marker anti-phosphohistone H3, have been proposed to objective subjectivities in mitosis assessment ⁶⁴, but the experience is still limited and there are no objective methods to account for tumor cell necrosis. The use of Ki-67 antigen could simplify this evaluation of proliferation activity, but overlap existing

between adjacent tumor categories and quantification modalities^{12, 29} prevented to exploit this marker as defining criterion of lung NET according to current guidelines^{1, 4}.

Recognition of lung NET, especially in non-resection samples, is recommended by using IHC for pan-NE (synaptophysin, chromogranin A, hASH1) and epithelial markers (cytokeratin pools), in keeping with recent guidelines and classifications^{1, 4}. Worth mentioning is the application of always-negative-markers, such as high molecular weight cytokeratins^{65, 66} or p40⁶⁷, whereas p63 may be consistently expressed by SCC⁶⁸. It should be kept in mind that many nuclear transcription factors used for differentiating NET arising in diverse anatomical sites, such as TTF-1, Islet-1, PAX-8 and CDX2, hold true for well-differentiated tumors only, i.e. TC and AC, as LCNEC and SCC can be associated with aberrant and illegitimate expression of these markers regardless of their origin (**Figure 3**).

Unraveling Ki-67 and tumor grading

As outlined above, current criteria for lung NET basically include mitosis count and necrosis¹², whilst tumor architecture, cell atypia, vascular invasion, lymph node metastases or immunohistochemistry profile do not play any role in this separation^{14, 17}. However, some controversies still persist in their diagnostic reproducibility, so that searching for additional criteria more related to behavioral traits is clinically warranted.

Ki-67 antigen has been largely studied in lung NET^{12, 25, 29, 69}, with several features regarding technical issues, evaluation of results, diagnostic role, prognostic role (including tumor grading), and predictive role in therapeutic decisions being recently reviewed⁶⁹. There are different options to quantify Ki-67 antigen in lung NET (the product of MKI67 gene mapping to 10q26.2 gene acting as a non-histone nuclear protein involved in all active stages of the cell cycle, but not in resting cells), most often carried out upon immunohistochemistry by using the clone MIB-1 and expressed as the percentage of positive tumor cells (labeling index, LI), i.e. manual counting, digital image analysis or eyeball estimation⁶⁹. Most published investigations agreed on the opportunity of measuring Ki-67 LI in hot spot areas, taking into account all nuclear signals after visual scrutiny of the entire tumor area⁶⁹. This would apply especially to TC or AC, whereas Ki-67 decoration is usually much more uniform in high-grade NE tumors. For practical purposes, Ki-67 LI should be calculated in surgical specimens by

counting at least 2000 consecutive tumor cells in hot spot fields at 40x magnification or 2 mm² for consistency with the histological classification, possibly in the same tumor areas as those used for assessing mitotic count⁶⁹. In biopsy or cytology samples, in which the number of tumor cells may be lower than 2000 or the 2-mm² criterion not necessarily met, it could be reasonable to calculate Ki-67 LI on all tumor cells. For experienced pathologists, however, manual counting of Ki-67 LI upon visual inspection or eyeball estimation differs little from more sophisticated, time-consuming, or cumbersome methods^{13, 70}. Although there are significant differences in the mean/median thresholds of Ki-67 LI amongst TC, AC, LCNEC and SCC^{61, 62, 69, 71-74}, some overlap existing between adjacent tumor categories prevented to establish a decisional role to this marker relative to histological classification^{1, 17} simply because mitoses, necrosis and Ki-67 antigen look at different biological phenomena⁶⁹, albeit they are somewhat related to each other in terms of overwhelming behavioral impact²⁹. Reproducibility studies on Ki-67 LI assessment revealed encouraging results^{56, 75}, with less than 1.5% of variability⁷⁵ and an out-performance of Ki-67 LI over mitotic count with regard to inter-observer agreement⁵⁶.

Ki-67 LI has a major value in distinguishing TC and AC from high-grade NET^{71, 73, 74}, especially when small crushed biopsy samples or cytology are dealt with (with a practical cut-off point of 25% to operate this distinction)^{12, 13, 71, 73, 74}, as well as in differentiating between lower and higher malignant NE tumors in resection specimens of TC and AC (with cut-off thresholds ranging from 4% to 5%)^{13, 37, 54, 75-78} in keeping with pancreatic NE tumors^{79, 80}, albeit sometimes with a non-independent value upon multivariate analysis⁷⁵. Although conceptually reasonable, few studies have so far addressed a role of Ki-67 LI in the prognostic stratification of poorly differentiated NE tumors in the lung¹³, at variance with what has been proposed in other endocrine organs, such as the pancreas^{81, 82}.

Tumor grading is a way to unravel the inherent aggressiveness of tumors exactly as the temperature correlates with the thermal energy of a body according to its average status of molecular agitation. Just like temperature, grading should be an intensive property of tumors independent of, albeit correlated with, tumor stage. In other words, grading would define the level of biological recruitment of tumors, correlated with but not completely overlapping with cell differentiation, which alone cannot exhaustively anticipate biological

behavior of tumors. As a matter of fact it is possible to diversify subsets of patients with different life expectation in the histological categories of lung NET^{32, 35, 36, 83}. This is the reason why grading systems based on the histological definition of disease may be not completely satisfying to take operational decisions in the clinical management of patients, especially in tumors where defining histological criteria are broader, such as AC or LCNEC²⁹.

Grading of lung NET according to histology/cell differentiation is inherently present in the current WHO classification scheme¹. Accordingly, TC is low-grade malignant, AC intermediate-grade malignant, and LCNEC and SCLC high-grade malignant NET^{1, 4, 11, 46, 48}. In particular, SCC and TC are so agreed-upon tumor entities in the lung to seem too reductive to simply call them G3 and G1 tumors, respectively. However, establishing a grading system in lung NET independent of histology could be clinically warranted in individual tumor patients for the personalized therapy requirements, in keeping with the lesson of GEP-NET. Naturally, this grading system should rely on different defining criteria in the lung compared to GEP-NET or other anatomical locations, as there are profound differences in biological behavior for tumors arising in different sites^{29, 80, 84-86}. Such a system should hopefully be independent of staging to take clinical decisions also in the metastatic setting of disease in accordance with the biological characteristics of tumors. An innovative grading method in resection specimens has recently been proposed for lung NET, which jointly included Ki-67, mitotic rate and necrosis, each parameter being further tiered according to three different expression levels independent at multivariate analysis (**Table 3**)¹³. In particular, G1 tumors were defined if at least 2 out of 3 parameters were at the level 1; G2 if at least 2 out of 3 parameters were at the level 2; and G3 if at least 2 out of 3 parameters were at the level 3. The combined assessment of these three parameters outperformed each individual parameter in predicting patient overall survival, resulting in a G1 to G3 grading system showing minimal overlap of 95% confidence intervals among these three defining categories. Interestingly, all TC clustered into the G1 category whilst a small fraction of SCC and LCNEC were classified into the G2 category in keeping with the clinical observation that a small fraction of these patients pursues an unexpected less aggressive clinical course despite histological diagnosis^{36, 61, 62}. Importantly AC were split into all the three tumor grades reflecting the inherent behavioral heterogeneity of AC, some of which behave very similarly to TC whereas others are much

more aggressive, not diversely from poorly differentiated lung NET⁶⁰. These findings are likely to reflect the subjective interpretation of AC vs. TC or LCNEC when morphology is the only discriminating factor^{15, 16, 55}. Certainly many efforts will be needed for validating this grading proposal in lung NET by accruing independent tumor series in resection specimens, as well as for setting up a reliable grading system in small samples, which often are the only available material at the time of the initial diagnosis or in tumor metastases, where grading tumors could have clinical relevance⁴ just like in GEP-NET⁸⁴⁻⁸⁶.

Predicting in NET

According to recent guidelines, no molecular tests should currently be routinely carried out in lung NET, unless specifically required by study protocols (*Level of Evidence 4; Grade of Recommendation C*)⁴. However, an increasing body of knowledge is accumulating in lung NET about biomarkers with predictive value, which could modify the therapy of these tumors in near future. This holds true especially for TC and AC where treatment, when non directly surgical (as mainly happens), relies on multimodality approaches or non-conventional drugs, whilst LCNEC and SCLC are generally cured by exclusive chemo-radiotherapy^{87, 88}.

In this setting of predictive biomarkers, Ki-67 LI does not play a decisive role in lung NET beyond refining better diagnostic recognition in demanding cases, for instance when occurring severe crush artifacts in small tissue samples⁷¹. Ki-67 antigen is independent of or weakly associated with thymidylate synthase expression, an enzyme involved in DNA synthesis whose presence acts as a resistance factor to fluoropyrimidine therapy in tumors, including NET⁸⁹, as well as with excision repair cross-complementation 1 (ERCC 1) expression, a resistance factor against platinum-based chemotherapy in lung cancer⁹⁰, or mammalian target of rapamycin (m-TOR) signaling activation pathways, an attractive target for inhibitors such as everolimus⁶¹. Thus far, no randomized clinical trials have documented that establishing Ki-67 LI in lung NE tumors may help to guide the subsequent therapy, just like in NSCLC⁹¹.

In lung NET, there are several potential predictive factors, which could become eligible for clinical trials, on which it is warranted to accumulate more information for better personalizing therapy⁹², including antifolate chemotherapy, somatostatin receptors, m-TOR

signaling pathway molecules and a miscellaneous of other factors. According to the lesson of tamoxifen in breast cancer ⁹³, it has been demonstrated that the thresholds of thymidylate synthase evaluated by adopting either mRNA quantitative PCR ⁸⁹ or semiquantitative protein expression upon IHC ⁹⁴ were significantly higher in LCNEC and SCC than AC and TC or NSCLC indicating a different level of responsiveness to fluoropyrimidine therapy with longer time to progression of 5-fluorouracil-treated lung NET patients with lower expression of this biomarker ⁸⁹. Somatostatin receptors are well-known targets for analogue drug therapy in GEP-NET ^{95, 96}, but an emerging role is playing also in the control of non-surgical cases of well-differentiated lung NET due to their anti-proliferation activity and hormone secretion inhibition ^{4, 97}. Somatostatin receptors can be easily assayed by IHC on tumor sections and a reliable scoring system has also been devised, which accurately correlates with *in vivo* imaging upon octreoscan ^{62, 98}, opening the way to its routine use especially in the setting of non-operable lung NET ⁹⁹. Targeting m-TOR pathway with specific inhibitors, such as everolimus, in lung well-differentiated NET results in anti-proliferative activity likely due to reduction of VEGF secretion and IGF1 signaling inhibition ¹⁰⁰. Molecules involved in the downstream m-TOR activation pathway, such as phosphorylated m-TOR, AKT, p70S6K and ERK1/2 (MAPK3/1) ¹⁰¹, can be all easily assayed by IHC upon tumor tissue sections ⁶¹. Concurrent inactivation of m-TOR and PI3K pathways (for instance by using dual PI3K/mTOR inhibitor NVP-BEZ235) gave rise to more potent effects than everolimus alone in reducing the proliferation of human bronchial carcinoid cells, with resistant tumor cells displaying lower levels of mTOR, p70S6K, AKT and ERK1/2 ¹⁰¹. These findings indicate that looking for these proteins may be useful to predict sensitiveness for high protein levels or resistance for low protein levels to synergic m-TOR and PI3K/m-TOR inhibitor treatment in well-differentiated NE proliferations, including carcinoids and DIPNECH ^{102, 103}. The pathway of m-TOR in lung NET is also related to energy and metabolism regulation by expression of GLUT1 and LAT1, the former being prevalent in high-grade NET with an inverse correlation with m-TOR and somatostatin receptor type 2 expression, the latter being prevalent in well-differentiated NET with direct correlation with somatostatin receptor type 2, survivin and angiopoietin II expression, independently of glucose or oxygen availability (Volante et al, manuscript in preparation). Additional molecular targets potentially useful in lung NET include c-

MET/phospho-cMET up-regulation via PAX5 activity in AC, SCC and LCNEC, where co-inhibition produced a synergistic effect in killing tumor cells, probably related to paxillin inactivation, which is a downstream target of activated c-MET involved in cell motility and tumor spread ¹⁰⁴. MET mutations are relatively rare in SCLC and others lung NET, they affect the juxtamembrane domain and are of no functional relevance as they do not influence c-Met phosphorylation, regardless of tyrosine kinase inhibitor treatment ¹⁰⁵. LCNEC patients present with variable c-KIT, Her-2/neu, VEGF PDGFR-alpha, PDGFR-beta protein overexpression but with no c-KIT or EGFR gene mutations or amplification ¹⁰⁶, suggesting a negative prognostic factor for c-KIT expression ^{107, 108} and a potential therapeutic effect for anti-VEGF-, anti-c-KIT- and possibly anti-HER2-targeted agents in the treatment of these tumors ^{108, 109}. The same LCNEC show preferential expression of potential markers for cancer stem cells, including aldehyde dehydrogenase 1 family member A1, aldo-keto reductase family 1 members C1 and C3 and CD44 antigen, which could have diagnostic and prognostic implications in these tumors ¹¹⁰. The differential expression of CD44, orthopedia transcription factor and menin, the product of MEN-1 gene, and 11q22.3-q25 deletion in TC and AC and of aurora B kinase and surviving in high-grade NE carcinomas may comprise therapeutic targets for these tumors ^{31, 83, 111}, as well as identify subpopulations of patients within each tumor category with different life expectation allowing a better risk stratification for therapy purposes ^{31, 35, 83}. A better understanding of the entire landscape of molecular alterations in lung NET affecting either genetic or epigenetic mechanisms would hopefully lead to a molecular classification in part heralded by recent next generation sequencing studies ^{26, 28, 112, 113}, where predictive biomarker assessment in the diverse tumor categories would help to identify different patient subpopulations suitable for personalized therapies.

Conclusion

Lung NET comprise a quite heterogeneous cluster of human malignancies with profound differences in the epidemiologic, genetic, pathologic and behavioral characteristics, which can cause a conundrum to the biological understanding of these lesions. Through an enlightened re-thinking of lung NET, pathologists should provide clinicians with better diagnostic refining of the diverse categories of lung NET with closer adherence to the clinical reality by means of an innovative concept of tumor grading. Additionally, they should clarify the meaning of Ki-67 LI in the practical clinical management of patients and offer expertise and knowledge about molecular, genetic and predictive (therapeutic) factors that could be meaningful for clinical purposes. The final goal is to unravel the inherent complexity of lung NET to finally increase our options of therapy in these tumor patients.

Figure legends

Figure 1. Typical carcinoid of the lung (no necrosis; 1 mitosis/2 mm²) with nuclear pleomorphism in tumor cells: this feature is not *per se* diagnostic of atypical carcinoid.

Figure 2. Representative pictures of lung NET are shown according to the current 2015 WHO classification on resection specimens. Typical carcinoid is composed of trabecular arrangement of polygonal tumor cells with no necrosis and one mitotic figure only per 2 mm² (A), sometimes featuring spindle cell appearance especially in peripheral lung location (B). Atypical carcinoid exhibits at least 2 mitoses per 2 mm² and/or punctate necrosis (C), whereas large-cell neuroendocrine carcinoma shows organoid architecture with extensive necrosis (D), plentiful mitoses and with peripheral palisading (E). In turn, small cell carcinoma presents with small-sized tumor cells with very scant cytoplasm and innumerable mitotic figures (F).

Figure 3. This case of small cell carcinoma (A) showed high Ki-67 labeling index (B), faint and punctate positivity for cytokeratin pool (B, inset), strong and diffuse cytoplasmic decoration for synaptophysin (C) and scattered tumor cells positive for chromogranin A (C, inset). Unexpectedly, there was nuclear staining for transcription factors such as CDX-2 (D) and Islet-1 (E), whereas TTF-1 was diffusely positive as in most of these tumors (F).

References

1. Travis W, Brambilla E, Burke A, Marx A, Nicholson A. *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart*. Fourth Ed. ed. Lyon: IARC Press; 2015.
2. Travis W, Colby T, Corrin B, Shimosato Y, Brambilla E. *Hystological typing of lung and pleural tumours*. Berlin Heidelberg New York: Springer Verlag; 1999.
3. Travis W, Brambilla E, Muller-Hermelink H, Harris C. *Tumours of the lung, pleura, thymus and heart*. Lyon: IARC Press; 2004.
4. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol*. 2015;26:1604-1620.
5. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. *Am J Surg Pathol*. 2002;26:1184-1197.
6. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. *Hum Pathol*. 1998;29:272-279.
7. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. *Am J Surg Pathol*. 1998;22:934-944.
8. Kunz PL. Carcinoid and neuroendocrine tumors: building on success. *J Clin Oncol*. 2015;33:1855-1863.
9. Godwin JD, 2nd, Brown CC. Comparative epidemiology of carcinoid and oat-cell tumors of the lung. *Cancer*. 1977;40:1671-1673.
10. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. *J Clin Oncol*. 2006;24:70-76.
11. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. *Hematol Oncol Clin North Am*. 2007;21:395-407; vii.

12. Pelosi G, Hiroshima K, Mino-Kenudson M. Controversial issues and new discoveries in lung neuroendocrine tumors. *Diagn Histopathol*. 2014;20:392-397.
13. Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. *Endocr Relat Cancer*. 2014;21:1-16.
14. Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. *Thorac Surg Clin*. 2014;24:257-266.
15. den Bakker MA, Thunnissen FB. Neuroendocrine tumours--challenges in the diagnosis and classification of pulmonary neuroendocrine tumours. *J Clin Pathol*. 2013;66:862-869.
16. den Bakker MA, Willemsen S, Grunberg K, et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. *Histopathology*. 2010;56:356-363.
17. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *J Thorac Oncol*. 2015;10:1243-1260.
18. Filosso PL, Guerrera F, Evangelista A, et al. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Groupdagger. *Eur J Cardiothorac Surg*. 2015;48:441-447.
19. Lou F, Sarkaria I, Pietanza C, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. *Ann Thorac Surg*. 2013;96:1156-1162.
20. Mete O, Asa SL. Precursor lesions of endocrine system neoplasms. *Pathology*. 2013;45:316-330.
21. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. *Virchows Arch*. 1995;425:547-560.
22. Franks TJ, Galvin JR. Lung tumors with neuroendocrine morphology: essential radiologic and pathologic features. *Arch Pathol Lab Med*. 2008;132:1055-1061.

23. Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. *Am J Clin Pathol*. 2001;116:466-472.
24. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. *J Thorac Oncol*. 2010;5:436-441.
25. Rekhtman N. Neuroendocrine tumors of the lung: an update. *Arch Pathol Lab Med*. 2010;134:1628-1638.
26. Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. *Nat Commun*. 2014;5:3518.
27. Iwakawa R, Takenaka M, Kohno T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. *Genes Chromosomes Cancer*. 2013;52:802-816.
28. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet*. 2012;44:1104-1110.
29. Pelosi G, Papotti M, Rindi G, Scarpa A. Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors. *Endocr Pathol*. 2014.
30. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. *Nat Genet*. 2012;44:1111-1116.
31. Swarts DR, Claessen SM, Jonkers YM, et al. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. *Am J Pathol*. 2011;179:1129-1137.
32. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: Evidence for separate biological entities. *Biochim Biophys Acta*. 2012;1826:255-271.
33. (NGM) Tcicgpcangm. A genomics-based classification of human lung tumors. *Sci Transl Med*. 2013;5:209ra153.

34. Toffalorio F, Belloni E, Barberis M, et al. Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. *Br J Cancer*. 2014;110:1244-1249.
35. Swarts DR, Henfling ME, Van Neste L, et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. *Clin Cancer Res*. 2013;19:2197-2207.
36. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. *Lancet*. 2004;363:775-781.
37. Pelosi G, Pasini F, Fraggetta F, et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. *Lung Cancer*. 2003;42:203-213.
38. Azzopardi J. Oat-cell carcinoma of the bronchus. *J Path Bact*. 1959;78:513-519.
39. Barnard W. The nature of the oat-celled sarcoma of the mediastinum. *J Path Bact*. 1926;29:241-244.
40. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. *J Thorac Cardiovasc Surg*. 1972;64:413-421.
41. Hamperl H. Ueber gutartige Bronchilatumoren (Cylindrome und Carcinoide). *Virchows Archiv (Pathol Anat)*. 1937;300:46.
42. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. *Hum Pathol*. 2004;35:1440-1451.
43. Oberndorfer S. Karzinoide Tumoren des Dünndarms. *Frankfurter Zeischrift Pathol*. 1907;1:426-432.
44. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. *Am J Surg Pathol*. 1991;15:529-553.
45. Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. *Lab Invest*. 1983;49:519-537.

46. Cerilli LA, Ritter JH, Mills SE, Wick MR. Neuroendocrine neoplasms of the lung. *Am J Clin Pathol*. 2001;116 Suppl:S65-96.
47. Moran CA, Suster S, Coppola D, Wick MR. Neuroendocrine carcinomas of the lung: a critical analysis. *Am J Clin Pathol*. 2009;131:206-221.
48. Wick MR. Neuroendocrine neoplasia. Current concepts. *Am J Clin Pathol*. 2000;113:331-335.
49. Paladugu RR, Benfield JR, Pak HY, Ross RK, Teplitz RL. Bronchopulmonary Kulchitzky cell carcinomas. A new classification scheme for typical and atypical carcinoids. *Cancer*. 1985;55:1303-1311.
50. Axiotis C. The neuroendocrine lung. In: Li Volsi V, Asa S, eds. *Endocrine Pathology*. New York Edinburgh: Churchill Livingstone; 2002:261-296.
51. Huang Q, Muzitansky A, Mark EJ. Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. *Arch Pathol Lab Med*. 2002;126:545-553.
52. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. *Digestion*. 1994;55 Suppl 3:11-23.
53. Solcia E, Klöppel G, Sobin L. *Histological typing of endocrine tumours*. 2nd ed. ed. Heidelberg: Springer; 2000.
54. Zahel T, Krysa S, Herpel E, et al. Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. *Virchows Arch*. 2012;460:299-308.
55. Swarts DR, van Suylen RJ, den Bakker MA, et al. Interobserver variability for the WHO classification of pulmonary carcinoids. *Am J Surg Pathol*. 2014;38:1429-1436.
56. Warth A, Fink L, Fisseler-Eckhoff A, et al. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. *Virchows Arch*. 2013;462:507-513.
57. Ha SY, Han J, Kim WS, Suh BS, Roh MS. Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis. *Korean J Pathol*. 2012;46:42-47.

58. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. *Ann Thorac Surg.* 2007;84:702-707.
59. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. *Virchows Arch.* 2007;451 Suppl 1:S51-59.
60. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. *Hum Pathol.* 2000;31:1255-1265.
61. Righi L, Volante M, Rapa I, et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. *Endocr Relat Cancer.* 2010;17:977-987.
62. Righi L, Volante M, Tavaglione V, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. *Ann Oncol.* 2010;21:548-555.
63. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. *Cancer.* 2011;117:3416-3423.
64. Tsuta K, Liu DC, Kalhor N, Wistuba, II, Moran CA. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. *Am J Clin Pathol.* 2011;136:252-259.
65. Papotti M, Sapino A, Righi L, Chiappone S, Bussolati G. 34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. *Appl Immunohistochem Mol Morphol.* 2001;9:229-233.
66. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. *Hum Pathol.* 2001;32:918-925.
67. Pelosi G, Rossi G, Cavazza A, et al. DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. *Int J Surg Pathol.* 2013;21:229-239.

68. Pelosi G, Pasini F, Olsen Stenholm C, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? *J Pathol.* 2002;198:100-109.
69. Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. *J Thorac Oncol.* 2014;9:273-284.
70. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. *Am J Surg Pathol.* 2012;36:1761-1770.
71. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. *Am J Surg Pathol.* 2005;29:179-187.
72. Wang H, Iyoda A, Roh MS, et al. WHO histologic classification is an independent predictor of prognosis in lung neuroendocrine (NE) tumors but Ki-67 proliferation rate is not (abstract #1952). *Mod Pathol.* 2013;26:469A.
73. Aslan DL, Gulbahce HE, Pambuccian SE, Manivel JC, Jessurun J. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. *Am J Clin Pathol.* 2005;123:874-878.
74. Lin O, Olgac S, Green I, Zakowski MF, Klimstra DS. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. *Am J Clin Pathol.* 2003;120:209-216.
75. Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. *Mod Pathol.* 2012;25:1258-1264.
76. Costes V, Marty-Ane C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. *Hum Pathol.* 1995;26:740-745.

77. Grimaldi F, Muser D, Beltrami CA, et al. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. *Front Endocrinol (Lausanne)*. 2011;2:20. Epub 2011 Aug 2019.
78. Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. *Clin Cancer Res*. 2008;14:149-154.
79. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. *Hum Pathol*. 1996;27:1124-1134.
80. Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. *J Natl Cancer Inst*. 2012;104:764-777.
81. Bastrurk O, Yang Z, Tang L, et al. Increased (>20%) Ki-67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival (abstract #1761). *Mod Pathol*. 2013;26:423A.
82. Basturk O, Tang L, Hruban RH, et al. Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas: A Clinicopathologic Analysis of 44 Cases. *Am J Surg Pathol*. 2014.
83. Swarts DR, Scarpa A, Corbo V, et al. MEN1 Gene Mutation and Reduced Expression Are Associated With Poor Prognosis in Pulmonary Carcinoids. *J Clin Endocrinol Metab*. 2014;99:E374-378.
84. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. *Am J Surg Pathol*. 2010;34:300-313.
85. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. *Pancreas*. 2010;39:707-712.

86. Yang Z, Tang LH, Klimstra DS. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. *Semin Diagn Pathol.* 2013;30:186-196.
87. Gridelli C, Rossi A, Airoma G, et al. Treatment of pulmonary neuroendocrine tumours: State of the art and future developments. *Cancer Treat Rev.* 2013;39:466-472.
88. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. *J Thorac Oncol.* 2015;10:1133-1141.
89. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. *Clin Cancer Res.* 2008;14:1059-1064.
90. Skov BG, Holm B, Erreboe A, Skov T, Møllegaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. *J Thorac Oncol.* 2010;5:453-459.
91. Jakobsen JN, Sørensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. *Lung Cancer.* 2013;79:1-7.
92. Abrahams E. Right drug-right patient-right time: personalized medicine coalition. *Clin Transl Sci.* 2008;1:11-12.
93. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. *Eur J Cancer.* 2008;44:30-38.
94. Monica V, Scagliotti GV, Ceppi P, et al. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. *Clin Cancer Res.* 2009;15:7547-7552.
95. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med.* 2014;371:224-233.
96. Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. *Gastrointest Cancer Res.* 2012;5:161-168.
97. Zatelli MC, Maffei P, Piccin D, et al. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. *J Clin Endocrinol Metab.* 2005;90:2104-2109.

98. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. *Mod Pathol*. 2007;20:1172-1182.
99. Pelosi G, Volante M, Papotti M, Sonzogni A, Masullo M, Viale G. Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. *Q J Nucl Med Mol Imaging*. 2006;50:272-287.
100. Zatelli MC, Minoia M, Martini C, et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. *Endocr Relat Cancer*. 2010;17:719-729.
101. Gagliano T, Bellio M, Gentilin E, et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. *Endocr Relat Cancer*. 2013;20:463-475.
102. Righi L, Volante M, Rapa I, Vatrano S, Pelosi G, Papotti M. Therapeutic biomarkers in lung neuroendocrine neoplasia. *Endocr Pathol*. 2014;25:371-377.
103. Rossi G, Cavazza A, Graziano P, Papotti M. mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. *Am J Respir Crit Care Med*. 2012;185:341; author reply 341-342.
104. Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. *Arch Pathol Lab Med*. 2010;134:1702-1705.
105. Voortman J, Harada T, Chang RP, et al. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. *Curr Pharm Des*. 2013;19:833-840.
106. Pelosi G, Scarpa A, Veronesi G, et al. A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. *Virchows Arch*. 2005;447:969-977.
107. Casali C, Stefani A, Rossi G, et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. *Ann Thorac Surg*. 2004;77:247-252; discussion 252-243.

108. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. *J Clin Oncol.* 2005;23:8774-8785.
109. Iyoda A, Travis WD, Sarkaria IS, et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. *Exp Ther Med.* 2011;2:1041-1045.
110. Nomura M, Fukuda T, Fujii K, et al. Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. *J Clin Bioinforma.* 2011;1:23.
111. Swarts DR, Van Neste L, Henfling ME, et al. An exploration of pathways involved in lung carcinoid progression using gene expression profiling. *Carcinogenesis.* 2013;34:2726-2737.
112. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. *Nature.* 2015;524:47-53.
113. Fernandez-Cuesta L, Peifer M, Lu X, et al. Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets (abstract #1531). *AACR Annual Meeting of the American Association of Cancer Research.* San Diego (CA) 2014.

Table 1. Pros and cons about the current classification of pulmonary neuroendocrine tumors

<i>Pros</i>	Cons
WHO terminology is widely agreed-upon, with wide clinics and pathology experience	Inconsistencies in tumor diagnostic reproducibility among different observers
	Troubles in the multimodality therapy of AC and LCNEC
TC, AC and SCLC/LCNEC are so distinctive tumors that it seems reductive to simply call them G1, G2 and G3	Any classification should be clinically useful, also in metastatic tumors or within the same tumor categories (e.g., TC or AC or LCNEC or SCC)
There are sharp differences in the therapy, prognosis and diagnosis of SCLC and TC	Epidemiologic, clinical & genetic data favor a 3-tier over a 4-tier classification scheme
TC: typical carcinoid; AC: atypical carcinoid; LCNEC: large-cell neuroendocrine carcinoma; SCC: small cell carcinoma	

Table 2. Diagnostic criteria for lung neuroendocrine tumors according to WHO 2015 classification

Variable	Typical carcinoid	Atypical carcinoid	Large-cell neuroendocrine carcinoma	Small-cell carcinoma
Neuroendocrine morphology	yes	yes	yes	yes
Cytologic criteria	no	no	yes	yes
Mitoses/2 mm²	1	2-10	≥ 11	≥ 11
Necrosis	no	punctate	extensive	extensive
Combined variant	no	no	yes	yes
Ki-67 labeling index	up to 5%	up to 25%	40-80%	50-100%

Table 3. Grading system parameters in lung neuroendocrine tumors

Cut-off levels	Variable		
	Mitoses (10 HPF or 2 mm ²)	Ki-67 LI	Tumor necrosis
Level 1	2	< 4	absent
Level 2	>2 - 47	4 - 25	< 10%
Level 3	> 47	≥ 25	> 10%

Ki-67 LI: Ki-67 labeling index, percentage of immunoreactive tumor cells; for details on application of the grading system see the text and reference #13





